Protalix BioTherapeutics Overview

Protalix BioTherapeutics EBIT

EBIT (Earnings Before Interest and Taxes) analysis for PLX.

Quarterly EBIT

$20.74M

↑ 656.68% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

$15.24M

↑ 195.25% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin